Cancer immunotherapy: an embarrassment of riches? 2003

Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
Onyvax, St George's Hospital Medical School, Cranmer Terrace, London, UK SW17 0RE. mwhelan@onyvax.com

There is clear evidence that certain forms of immunotherapy can be successful against certain cancers. However, it would appear that cancerous cells of various origin are exceptionally adept at subverting the immune response. Consequently, it is probable that the most efficacious therapy will be one in which multiple responses of the immune system are activated. There is currently an embarrassment of riches with regard to multiple vaccine strategies in the clinic, although no single method seems to hold the solution. Here, we draw together several of the humoral- and cellular-activating strategies currently under clinical investigation.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D019139 Tumor Escape The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 ANTIGENS and B7-1 ANTIGEN. Immune Escape, Tumor,Immune Evasion, Tumor,Tumor Immune Evasion,Evasion, Tumor Immune,Evasions, Tumor Immune,Immune Evasions, Tumor,Tumor Immune Escape,Tumor Immune Evasions
D019496 Cancer Vaccines Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. Cancer Vaccine,Neoplasm Vaccines,Tumor Vaccine,Tumor Vaccines,Vaccines, Cancer,Vaccines, Neoplasm,Vaccines, Tumor,Vaccine, Cancer,Vaccine, Tumor

Related Publications

Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
January 2001, The Journal of the American College of Dentists,
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
October 2014, Pediatrics,
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
November 1989, Obstetrics and gynecology,
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
October 2023, ANZ journal of surgery,
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
March 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
January 2002, Annals of neurology,
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
February 1995, Science (New York, N.Y.),
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
January 1992, Science (New York, N.Y.),
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
August 2021, Current opinion in plant biology,
Mike Whelan, and Joseph Whelan, and Nick Russell, and Angus Dalgleish
July 2016, European urology,
Copied contents to your clipboard!